Navigation Links
Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
Date:8/4/2009

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 29th Annual Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at the Boston InterContinental Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
2. Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
3. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
8. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
9. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
11. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
(Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
(Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
Breaking Medicine Technology: